Sanofi

Aileron Therapeutics, Inc.

Jiawen Han

Daniel J Tavares

Michel Streuli

Chonghui Zhang

Veronique Blanc

Fabienne Parker

Claudia Fromond

Min Li

Xiao-Mai Zhou

Rosana Kapeller-Libermann

Tomi K Sawyer

Huw M Nash

Noriyuki Kawahata

David Allen Annis

Véronique Blanc

Min Immunogen Inc Li

Antagonistic antibodies that specifically bind to and inhibit Class A Eph receptors are provided. Also provided are cytotoxic conjugates, pharmaceutical compositions and kits comprising these antibodies.

EPHA2 receptor antagonist antibodies

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the A class of Eph receptors.

Methods of use for antibodies that specifically bind to the EphA2 receptor

The present invention provides biologically active peptidomimetic macrocycles for the treatment of cell proliferative disorders such as cancer and immunoproliferative disease.

Therapeutic peptidomimetic macrocycles

Growing community of inventors

Newton, MA, United States of America

Jiawen Han